Educational research tool. Not investment advice. You are responsible for your own trading decisions.

Verdix.
← All analysis

Palo Alto Networks, Inc. (PANW)

Verdict history · PANW

Every call Verdix has made on PANW.

While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.

See methodology for how verdicts are produced. Full track record →

Why the panel isn’t ready to call PANW yet — and where they disagree.

WaitHIGH confidence

A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.

NASDAQ · Cybersecurity (Enterprise Software) · 2026-08-04 · analysis, not advice

Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.

The panel's take

Verdict: WAIT · Conviction: HIGH · Last price: USD 359.94 (as of 2026-08-04)

Palo Alto Networks just rallied to an all-time high on a strong fiscal Q3 print, and the panel's read is unusually clean for a first look: every one of six investing frameworks — spanning valuation, growth, contrarian, quality, scuttlebutt, and macro lenses — lands Neutral or Bearish, and not one disputes that the underlying business is genuinely strong. The debate isn't whether Palo Alto Networks is a good company; it's whether 97x GAAP earnings and 40x EV/EBITDA already price in a flawless integration of two large, simultaneous acquisitions. WAIT, not SELL, because the objection across the panel is price and timing, not the business itself — and there's an identifiable trigger on both sides of that price.

Key levels

Key levels · PANW

USD · as of 2026-08-04
Analyst consensus 359.94
R3368.8
+2.5%
S1285.67
−20.6%
S2254.19
−29.4%
S3227.5
−36.8%
NOW
359.94

Analyst consensus target 359.94 USD · range 344.87359.94

Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.

Key resistance sits at USD 368.80 — the stock's all-time high, just above the current price — with key support layered at USD 285.67, USD 254.19, and a deeper historical accumulation zone at USD 227.50. The analyst consensus target of USD 344.87 (42 analysts) currently sits below the stock's own price.

What legendary investors think

We ran Palo Alto Networks past a panel of 6 legendary investors' frameworks.

The panel · 6 investors

🟢
0
Bullish
4
Neutral
🔴
2
Bearish
The Intrinsic-Value ModelerValuation/DCF🔴 BearishMed

Signal: A base-case DCF (15% organic growth fading to a 4% terminal rate, 20% GAAP margin by year eight) yields $225–$280 a share against a $360 price — even the bull-case scenario tops out at $340, below where the stock trades today. Conviction: Conviction is held at Med because the range depends on integration execution that hasn't been proven yet, but every scenario in the sensitivity table — bull included — comes in under the current price.

The GARP OperatorGrowth (GARP) NeutralMed

Signal: The headline growth of 22% collapses to 12–18% once CyberArk and Chronosphere are stripped out, putting this in Stalwart territory at a PEG above 3.5 — well past the level where the framework calls a stock overvalued. Conviction: Conviction sits at Med because the balance sheet (near net cash) provides a real floor, but the widening gap between GAAP and adjusted earnings is exactly the kind of thing that makes this framework uncomfortable.

The Forensic SkepticContrarian/Forensic🔴 BearishMed

Signal: Stripping out acquisition-driven revenue and applying a conservative DCF puts intrinsic value at $180–$220 versus a $360 price — a negative margin of safety of 40–60% — while insiders sold $27.6M with zero purchases into the rally. Conviction: Conviction is held to Med because the FCF story is real, not fabricated; the disagreement is about what multiple that cash flow deserves, not whether it exists.

The Scuttlebutt Growth InvestorGrowth/Management NeutralMed

Signal: Palo Alto Networks scores 9 of 15 on the checklist — strong products, sales execution, and margins, but marked down on margin trajectory, accounting transparency, and heavy equity dilution from the acquisitions — a good business, not yet a great one at this price. Conviction: Conviction is Med because the framework explicitly separates quality from price here: the checklist score would need to climb, or the price would need to fall, for this to become a buy.

The Quality RationalistMental Models/Quality NeutralMed

Signal: The dual integration of two large acquisitions sits past the edge of a comfortably understandable business, and paying roughly 55x normalized earnings for organic growth of 12–15% is a good business priced for perfection, not a wonderful business at a fair one. Conviction: Conviction is Med — the moat and cash generation are real and hard to dispute, but the complexity genuinely limits how far this framework is willing to commit.

The Macro OpportunistMacro/Timing NeutralMed

Signal: With the Fed still running quantitative tightening and the 10-year yield near 4.2%, a high-duration, 97x-earnings stock rallying against a tightening backdrop is a divergence that historically resolves toward the macro, not against it — current risk/return skews toward a pullback before a fresh entry makes sense. Conviction: Conviction is Med, held back mainly by timing uncertainty — the sector tailwind is real, but the liquidity backdrop argues against chasing strength here.

Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.

Where they agree — and where they clash

Common ground

  • Headline revenue growth (~22–23%) is acquisition-inflated; every framework converges on 12–18% as the real organic growth rate once CyberArk and Chronosphere are excluded.
  • Insider activity is a shared concern: $27.6M sold in the trailing 90 days, zero purchases, even as the stock rallied roughly 25% into the print.
  • The Q3 guidance of $0.78–0.80 GAAP EPS came in below the pre-guidance Street figure of $0.92 — a real, near-term data point every voice references, not a hypothetical.
  • The technical setup is stretched by any measure: price sits 58% above the monthly 20-period average, both monthly and weekly RSI are above 70, and the stock is testing its all-time high.
  • Nobody disputes the moat is real — platformization, switching costs, and a $16B+ backlog of remaining performance obligations are treated as genuine strengths across every framework.

The real debate

  • How much to commit to a number: The Intrinsic-Value Modeler builds a full scenario range ($225–$340 across bear/base/bull) despite the uncertainty, while The Quality Rationalist declines to underwrite a precise figure at all, calling the dual integration "past the edge of a comfortably understandable business" — the same complexity read as a modeling input by one framework and a reason to abstain by another.
  • Quality versus price, kept separate or not: The Scuttlebutt Growth Investor explicitly separates the two — a 9-of-15 checklist score is "a good company, not yet a great one at this price" — while The Forensic Skeptic treats the valuation gap itself as the disqualifying fact, regardless of how the underlying business scores.
  • A dimension none of the company-specific frameworks weigh: The Macro Opportunist is the only voice bringing the liquidity backdrop — continued quantitative tightening and a 4.2% 10-year yield — into the call, arguing the stock's rally is running against, not with, the macro tide.
  • Outside the panel table, sentiment is the outlier. Both the sentiment and technical readings on this stock are constructive — sentiment is outright Bullish on the earnings beat and a string of analyst price-target increases, and even the technical read on trend structure is Bullish — but neither converts that into a case for a new position at the current price; the technical read's own recommendation is to hold existing positions rather than add. That's a full eight independent reads — six frameworks plus both scouts — landing on some version of "not here," even where the underlying signal is constructive.

The question it comes down to: Can Palo Alto Networks' organic growth and margin recovery outpace the multi-year amortization drag from its CyberArk and Chronosphere integration quickly enough to justify today's price — or does the stock need to come back down to meet the business before the case gets better?

The numbers

Metric Value
Price / Market cap USD 359.94 / n/a
P/E (TTM / fwd) n/a / 97x (GAAP)
ROE 3.0% (GAAP; ~16% adjusted)
Operating margin n/a
Dividend yield 0% (no dividends paid)
Debt / equity 0.07x
Free cash flow USD 3.15B (GAAP, TTM); ~4.2B adjusted

Figures as of 2026-08-04; sourced from Morningstar, TipRanks, and Capital Blueprint (fundamental_scout aggregation). Market cap and TTM P/E were not returned cleanly by the source query and are marked n/a rather than estimated from a stale price.

The bottom line

Watch the Q3 FY2026 print directly: consensus already sits below management's own pre-guidance figure at $0.78–0.80 GAAP EPS, so the real test is whether organic remaining-performance-obligation growth is still accelerating once the acquired backlog is separated out, and whether insider selling — zero purchases against $27.6M in sales over 90 days — shows any sign of reversing. A weekly close above USD 368.80 on strong volume would be the first evidence the market is willing to pay through the all-time high rather than stall at it; a close below USD 285.67 would confirm the stretched technical setup is resolving lower first. Until one of those levels resolves the standoff, the panel's read is that this is a business worth owning at a price the market hasn't offered yet.

contact@verdixhq.com · Published 2026-08-04 · Prices as of 2026-08-04 · Time horizon: 3–12 months · No direct position held in PANW · PANW verdict history → · Methodology →

Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.

Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.

Stay ahead of PANW's next verdict

The panel's view can flip on new earnings, a guidance cut, or a valuation shift. Get the update the moment it happens — not weeks later.

One email, only on a verdict change. Unsubscribe anytime.